Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q3 2025 · 10-Q
Revenue$187.80M$187.80M+11.9% vs Q3 2024 Net Income-$27.13M-$27.13MN/M vs Q3 2024 EPS Diluted-$0.21-$0.21N/M vs Q3 2024 Gross Profit$80,446,000+7.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Operating Cash Flowderived$8,884,000−3.9% Free Cash Flowderived$570,000N/M Margins · derivedGross margin42.8%−1.8 pt vs Q3 2024
Operating margin-14.4%−1.8 pt vs Q3 2024
Net margin-14.4%−3.9 pt vs Q3 2024
ended Sep 30, 2025 · filed Oct 28, 2025 · 28 d after period end